Conformal Conversion of Polyphosphazene@Sb2MoO6 Nanowires to N/S-Doped/Carbon-Coated SbPO4/MoOx for High-performance Lithium Storage.

Alloy-type antimony (Sb) and conversion-type molybdenum (Mo) anodes have attracted extensive attention in the application of lithium-ion batteries (LIBs) owing to their high theoretical capacity. In this study, Sb2MoO6 nanowires are prepared via a hydrothermal method and assessed their thermal behavior upon heat treatment, observing an intriguing transformation from nanowire to Sb2O3/MoOx nanosheets. To enhance structure stability, the Sb2MoO6 nanowires are successfully coated with a polyphosphazene layer (referred to as PZS@Sb2MoO6), which not only preserved the nanowires form but also yielded N/S co-doped carbon-coated SbPO4/MoOx (NS-C@SbPO4/MoOx) nanowires following annealing in an inert environment. This composite benefits from the stable PO4 3- anion that serve as a buffer against volume expansion and form a Li3PO4 matrix during cycling, both of which substantially bolster ion transport and cycle endurance. Doping with heteroatoms introduces numerous oxygen vacancies, augmenting the number of electrochemically active sites, and carbon integration considerably enhances the electronic conductivity of the electrode and alleviates the volume-change-induced electrode pulverization. Employed as anode materials in LIBs, the NS-C@SbPO4/MoOx electrode exhibits remarkable cycling performance (449.8 mA h g-1 at 1000 mA g-1 over 700 cycles) along with superior rate capability (394.2 mA h g-1 at 2000 mA g-1).

Case report: Successful sequential therapy of crizotinb and entrectinib in ROS1-positive non-small-cell lung cancer with brain metastasis in later-settings.

RATIONALE: Crizotinib has been approved in many countries for the treatment of patients with advanced ROS1-rearranged non-small cell lung cancers (NSCLC). Entrectinib is a ROS1 inhibitor that has been designed to effectively penetrate and remain in the central nervous system (CNS) and has been recommended as first-line therapy. Few reports have precisely described sequential crizotinb followed by entrectinib in patients with ROS1 fusion in later settings. PATIENT CONCERNS: A 56-year-old man with a history of occasional smoking visited our hospital with cough, sputum, and shortness of breath. DIAGNOSIS: He was diagnosed with right lung adenocarcinoma (T4N2M1a, stage IV) after image and histological examination, without EGFR or ALK fusion mutation. INTERVENTIONS: He received three prior lines of therapies, including chemotherapy, nivolumab monotherapy, and paclitaxel plus anlotinib, with progression-free survival (PFS) of 5, 2, and 11.5 months, respectively. Then the patient began to have headaches and dizziness, and brain magnetic resonance imaging showed multiple brain metastases. Next-generation sequencing (NGS) of the biopsy from neck lymph node identified EZR-ROS1 (1.25% abundance). After 2 months of crizotinib (250 mg daily) plus bevacizumab, all pulmonary and brain lesions decreased, but a small liver lesion was discovered. As treatment went on for another 4 months, the liver lesion continued to grow while other lesions kept decreased or stable state. NGS analysis on the peripheral blood found the disappearance of EZR-ROS1 fusion and a new NTRK2 mutation (c.5C>T, p.Ser2Leu, 0.34% abundance) without other targetable molecular alteration. He received entrectinib (600 mg daily) plus bevacizumab and achieved a partial response. After 7 months of therapy, examination revealed progression of brain lesions. OUTCOMES: The patient had a total PFS of 13 months from sequential crizotinib and entrectinib therapy. LESSONS: A ROS1-rearranged NSCLC with CNS metastases responded to sequential tyrosine kinase inhibitors treatment of crizotinb followed by entrectinib. This report has potential implications in guiding decisions for the treatment after crizotinib resistance.

Polyphosphazene-derived P/S/N-doping and carbon-coating of yolk-shelled CoMoO4 nanospheres towards enhanced pseudocapacitive lithium storage.

Transition metal oxides as potentialanodes of lithium-ion batteries (LIBs) possess high theoretical capacity but suffer from large volume expansion and poor conductivity. To overcome these drawbacks, we designed and fabricated polyphosphazene-coated yolk-shelled CoMoO4 nanospheres, in which polyphosphazene with abundant C/P/S/N species was readily converted into carbon shells and provided P/S/N dopants. This resulted in the formation of P/S/N co-doped carbon-coated yolk-shelled CoMoO4 nanospheres (PSN-C@CoMoO4). The PSN-C@CoMoO4 electrode exhibits superior cycle stability of 439.2 mA h g-1at 1000 mA g-1after 500 cycles and rate capability of 470.1 mA h g-1at 2000 mA g-1. The electrochemical and structural analyses reveal that PSN-C@CoMoO4 with yolk-shell structure, coated with carbon and doped with heteroatom not only greatly enhances the charge transfer rate and reaction kinetics, but also efficiently buffers the volume variation upon lithiation/delithiation cycling. Importantly, the use of polyphosphazene as coating/doping agent can be a general strategy for developing advanced electrode materials.

Association between psoriasis and lung cancer: two-sample Mendelian randomization analyses.

BACKGROUND: Observational studies reported an association between psoriasis and risk of lung cancer. However, whether psoriasis is causally associated with lung cancer is unclear. METHODS: Genetic summary data of psoriasis were retrieved from two independent genome-wide association studies (GWAS). Genetic information of lung cancer was retrieved from GWAS of International Lung Cancer Consortium. A set of quality control steps were conducted to select instrumental tools. We performed two independent two-sample Mendelian randomization (MR) analyses and a meta-analysis based on the two independent MR estimates to assess the causal relationship between psoriasis and lung cancer (LUCA) as well as its subtypes, squamous cell carcinoma (LUSC) and adenocarcinoma (LUAD). RESULTS: Between-SNP heterogeneity was present for most MR analyses, whereas horizontal pleiotropy was not detected for all MR analyses. Multiplicative random-effect inverse variance weighted (IVW-MRE) method was therefore selected as the primary MR approach. Both IVW-MRE estimates from the two independent MR analyses suggested that there was no significant causal relationship between psoriasis and LUCA as well as its histological subtypes. Sensitivity analyses using other four MR methods gave similar results. Meta-analysis of the two IVW-MRE derived MR estimates yielded an odds ratio (OR) of 1.00 (95% CI 0.95-1.06) for LUCA, 1.01 (95% CI 0.93-1.08) for LUSC, and 0.97 (95% CI 0.90-1.06) for LUAD. CONCLUSION: Our results do not support a genetic association between psoriasis and lung cancer and its subtypes. More population-based and experimental studies are warranted to further dissect the complex correlation between psoriasis and lung cancer.

Construction of the model for predicting prognosis by key genes regulating EGFR-TKI resistance.

Background: Previous studies have suggested that patients with lung adenocarcinoma (LUAD) will significantly benefit from epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI). However, many LUAD patients will develop resistance to EGFR-TKI. Thus, our study aims to develop models to predict EGFR-TKI resistance and the LUAD prognosis. Methods: Two Gene Expression Omnibus (GEO) datasets (GSE31625 and GSE34228) were used as the discovery datasets to find the common differentially expressed genes (DEGs) in EGFR-TKI resistant LUAD profiles. The association of these common DEGs with LUAD prognosis was investigated in The Cancer Genome Atlas (TCGA) database. Moreover, we constructed the risk score for prognosis prediction of LUAD by LASSO analysis. The performance of the risk score for predicting LUAD prognosis was calculated using an independent dataset (GSE37745). A random forest model by risk score genes was trained in the training dataset, and the diagnostic ability for distinguishing sensitive and EGFR-TKI resistant samples was validated in the internal testing dataset and external testing datasets (GSE122005, GSE80344, and GSE123066). Results: From the discovery datasets, 267 common upregulated genes and 374 common downregulated genes were identified. Among these common DEGs, there were 59 genes negatively associated with prognosis, while 21 genes exhibited positive correlations with prognosis. Eight genes (ABCC2, ARL2BP, DKK1, FUT1, LRFN4, PYGL, SMNDC1, and SNAI2) were selected to construct the risk score signature. In both the discovery and independent validation datasets, LUAD patients with the higher risk score had a poorer prognosis. The nomogram based on risk score showed good performance in prognosis prediction with a C-index of 0.77. The expression levels of ABCC2, ARL2BP, DKK1, LRFN4, PYGL, SMNDC1, and SNAI2 were positively related to the resistance of EGFR-TKI. However, the expression level of FUT1 was favorably correlated with EGFR-TKI responsiveness. The RF model worked wonderfully for distinguishing sensitive and resistant EGFR-TKI samples in the internal and external testing datasets, with predictive area under the curves (AUC) of 0.973 and 0.817, respectively. Conclusion: Our investigation revealed eight genes associated with EGFR-TKI resistance and provided models for EGFR-TKI resistance and prognosis prediction in LUAD patients.

Inhalation of MSC-EVs is a noninvasive strategy for ameliorating acute lung injury.

Mesenchymal stem cell-derived small extracellular vesicles (MSC-EVs) are promising nanotherapeutic agent for pneumonia (bacterial origin, COVID-19), but the optimal administration route and potential mechanisms of action remain poorly understood. This study compared the administration of MSC-EVs via inhalation and tail vein injection for the treatment of acute lung injury (ALI) and determined the host-derived mechanisms that may contribute to the therapeutic effects of MSC-EVs in lipopolysaccharide (LPS)-stimulated RAW 264.7 cells (macrophage cell line) and animal models. Luminex liquid chip and hematoxylin and eosin (HE) staining revealed that, compared with the vehicle control, inhaled MSC-EVs outperformed those injected via the tail vein, by reducing the expression of pro-inflammatory cytokines, increasing the expression of anti-inflammatory cytokine, and decreasing pathological scores in ALI. MSC-EV administration promoted the polarization of macrophages towards a M2 phenotype in vitro and in vivo (via inhalation). RNA sequencing revealed that immune and redox mediators, including TLR4, Arg1, and HO-1, were associated with the activity MSC-EVs against ALI mice. Western blotting and immunofluorescence revealed that correlative inflammatory and oxidative mediators were involved in the therapeutic effects of MSC-EVs in LPS-stimulated cells and mice. Moreover, variable expression of Nrf2 was observed following treatment with MSC-EVs in cell and animal models, and knockdown of Nrf2 attenuated the anti-inflammatory and antioxidant activities of MSC-EVs in LPS-stimulated macrophages. Together, these data suggest that inhalation of MSC-EVs as a noninvasive strategy for attenuation of ALI, and the adaptive regulation of Nrf2 may contribute to their anti-inflammatory and anti-oxidant activity in mice.

Chemical vapor deposition growth of carbon nanotube confined nickel sulfides from porous electrospun carbon nanofibers and their superior lithium storage properties.

Multidimensional architecture design is a promising strategy to explore unique physicochemical characteristics by synergistically integrating different structural and compositional materials. Herein, we report the facile synthesis of a novel dendritic hybrid architecture, where carbon nanotubes (CNTs) with nickel sulfide nanoparticles encapsulated inside are epitaxially grown out of the porous electrospun N-doped carbon nanofibers (CNFs) (denoted as CNT@NS@CNFs) through a combined strategy of electrospinning and chemical vapor deposition (CVD). The adopted thiophene (C4H4S) not only serves as a carbon source for the growth of CNTs but also as a sulfur source for the sulfurization of Ni particles and S-doping into carbon matrices. When examined as an anode material for lithium-ion batteries (LIBs), the dendritic CNT@NS@CNFs display superior lithium storage properties including good cycle stability and high rate capability, delivering a high reversible capacity of 630 mA h g-1 at 100 mA g-1 after 200 cycles and 277 mA h g-1 at a high rate of 1000 mA g-1. These outstanding electrochemical properties can be attributed to the novel hybrid architecture, in which the encapsulation of nickel sulfide nanoparticles within the CNT/CNFs not only efficiently buffers the volume changes upon lithiation/delithiation, but also facilitates charge transfer and electrolyte diffusion owing to the highly conductive networks with open frame structures.

Carbon-Supported Nickel Selenide Hollow Nanowires as Advanced Anode Materials for Sodium-Ion Batteries.

Carbon-supported nickel selenide (Ni0.85 Se/C) hollow nanowires are prepared from carbon-coated selenium nanowires via a self-templating hydrothermal method, by first dissolving selenium in the Se/C nanowires in hydrazine, allowing it to diffuse out of the carbon layer, and then reacting with nickel ions into Ni0.85 Se nanoplates on the outer surface of the carbon. Ni0.85 Se/C hollow nanowires are employed as anode materials for sodium-ion batteries, and their electrochemical performance is evaluated via the cyclic voltammetry and electrochemical impedance spectroscopy combined with ex situ X-ray photoelectron spectroscopy and X-ray diffraction measurements. It is found that Ni0.85 Se/C hollow nanowires exhibit greatly enhanced cycle stability and rate capability as compared to Ni0.85 Se nanoparticles, with a reversible capacity around 390 mA h g-1 (the theoretical capacity is 416 mA h g-1 ) at the rate of 0.2 C and 97% capacity retention after 100 cycles. When the current rate is raised to 5 C, they still deliver capacity of 219 mA h g-1 . The synthetic methodology introduced here is general and can easily be applied to building similar structures for other metal selenides in the future.

Polyvinylpyrrolidone-assisted ultrasonic synthesis of SnO nanosheets and their use as conformal templates for tin dioxide nanostructures.

Single crystalline SnO nanosheets with exposed {001} facets have been prepared by an ultrasonic aqueous synthesis in the presence of polyvinylpyrrolidone, which hinders the spontaneous formation of the truncated bipyramidal SnO microcrystals and exfoliate them into layer-by-layer hierarchical structures and further into separate SnO nanosheets. The SnO nanosheets have been used as conformal sacrificial templates converted into polycrystalline SnO(2), as well as layered SnO/SnO(2) nanostructures, by calcination in air. The concept of fabrication of two-dimensional tin oxide nanostructures demonstrated here may be relevant for the crystal design of layered materials, in general.